SITC20 Poster 237: In Vitro Potency Assays to Assess Next Generation Checkpoint Inhibitors
In Vitro Potency Assays for Immune Checkpoint Blockade using Human Primary Cells, Murine HuGEMM™ Immune Cells, and Patient-Derived Tumor Organoids
Xuefei Yan, Hongjuan Zhang, Jun Zhou, Jia Zheng, Shuang Zhu, Yahong Zhang, Rui Zhang, Mingfa Zang, Annie An, Xiaoxi Xu, Kevin Xu, Davy Xuesong Ouyang, Henry Li, and Yujun Huang
There’s an ever increasing demand for new assays with which to assess the in vitro potency of immune checkpoint modulators in immuno-oncology drug development.
In this poster, we present a platform of in vitro assays for assessing the effects of immune checkpoint blockade using human primary immune cells, humanized murine primary immune cells, and co-cultures of tumor cells or patient-derived tumor organoids with immune cells.
Download this Poster this to Discover:
- The validation of potency assays for immune checkpoint blockade using T cell activation and mixed lymphocyte reaction (MLR) assays
- How the co-culture of tumor cells or tumor organoids with allogenic T cells was established to measure the effects of PD-1 blockade on tumor cell killing, mediated by T cells and activation of T cells
- That HuGEMM mice, expressing engineered human immune checkpoint targets on immune cells, serve as an excellent resource of primary immune cells to test drug candidates targeting human checkpoints in vitro
Download the Poster Now!